CGONCG Oncology, Inc. Common stock

CSNasdaq (XNAS)·USD

Identity

Security key: 13335
Ticker: CGON
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2024-01-25
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CGON

Detail

Enriched 2026-08-14 20:47

Market cap: $6,824,422,471.25
Shares outstanding (class): 88,640,375
Shares outstanding (weighted): 88,640,375
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 142
Location: DALLAS, TX
Homepage: https://www.cgoncology.com
Description: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Market cap and share counts drift.

Funds holding this security

163 funds · 167 positions · $1.41B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, IN…	—	$174.27M	0.26%	2,574,868 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$148.50M	0.01%	2,194,218 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$107.00M	0.07%	1,580,911 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$97.71M	0.14%	1,443,706 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$86.42M	1.16%	1,276,920 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$75.03M	0.69%	1,108,573 NS	FIGI
VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS	VBR	$68.14M	0.11%	1,006,763 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$51.76M	0.06%	764,799 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$50.44M	0.22%	745,295 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$50.24M	0.39%	742,328 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$42.76M	0.52%	631,781 NS	FIGI
JNL/T. Rowe Price Capital Appreciation Fund JNL Series Trust	—	$38.57M	0.28%	569,851 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$32.70M	0.27%	483,212 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$25.67M	0.32%	379,295 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$24.80M	1.56%	366,397 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCGON
FIGI_COMPOSITEBBG00YHKK4Q3
FIGI_SHARE_CLASSBBG00YHKK4R2
CIK0001991792
ISINUS1569441009
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: CG Oncology is a clinical-stage biopharmaceutical company developing immunotherapies for cancer, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.